ID   IGROV-1/CP
AC   CVCL_IQ21
SY   IGROV-1-CP; IGROV1CP
DR   cancercelllines; CVCL_IQ21
DR   PRIDE; PXD003668
DR   Wikidata; Q54897385
RX   PubMed=16319398;
RX   PubMed=23913215;
RX   PubMed=27561551;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); ClinVar=VCV002724056; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Proteomics.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1304 ! IGROV-1
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 19
//
RX   PubMed=23913215; DOI=10.1007/978-1-62703-547-7_12;
RA   Li, Li-Sha
RA   Liu, Jie
RA   Yu, Wei
RA   Lou, Xiao-Yan
RA   Huang, Bing-Ding
RA   Lin, Biao-Yang
RT   "Deep transcriptome profiling of ovarian cancer cells using
RT   next-generation sequencing approach.";
RL   Methods Mol. Biol. 1049:139-169(2013).
//
RX   PubMed=16319398; DOI=10.1074/mcp.M500140-MCP200;
RA   Stewart, Jennifer J.
RA   White, James T.
RA   Yan, Xiao-Wei
RA   Collins, Steven J.
RA   Drescher, Charles W.
RA   Urban, Nicole D.
RA   Hood, Leroy Edward
RA   Lin, Biao-Yang
RT   "Proteins associated with cisplatin resistance in ovarian cancer cells
RT   identified by quantitative proteomic technology and integrated with
RT   mRNA expression levels.";
RL   Mol. Cell. Proteomics 5:433-443(2006).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645; PMCID=PMC5007461;
RA   Coscia, Fabian
RA   Watters, Karen M.
RA   Curtis, Marion
RA   Eckert, Mark A.
RA   Chiang, Chun-Yi
RA   Tyanova, Stefka
RA   Montag, Anthony
RA   Lastra, Ricardo R.
RA   Lengyel, Ernst Robert
RA   Mann, Matthias
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//